- Press Release Distribution

Two new clinical trials find first-ever safe and effective treatment to prevent multidrug-resistant TB in both children and adults: Results presented at the Union Conference in Paris

The TB-CHAMP Phase 3 Clinical Trial tested levofloxacin in children as part of the BENEFIT Kids project led by the Desmond Tutu TB Centre at Stellenbosch University and funded by global health organization Unitaid and others

( PARIS (16 November, 2023)—Two landmark clinical trials reported today at the Union meeting showed that an oral antibiotic taken for six months once-daily substantially reduced the risk of developing drug-resistant TB. The antibiotic levofloxacin safely reduced the risk of multidrug-resistant (MDR) tuberculosis (TB) disease in children by 56%, researchers from the Desmond Tutu TB Centre at Stellenbosch University announced at the Union Conference in Paris today. The Unitaid-funded trial also showed that levofloxacin given once daily to children over 6 months, was extremely safe. 

A second study, the VQUIN Trial, was presented at the same session. The VQUIN trial was conducted primarily among adults and adolescents, and found that levofloxacin reduced the risk of MDR-TB in adults and adolescents by 45%. Together, the two studies demonstrated that levofloxacin can stop the risk of MDR-TB among family and other household members, curtailing the global impact of this dangerous pathogen.

Evidence to date has been limited about MDR-TB preventive treatment since no randomized controlled trials had ever been conducted. TB-CHAMP took place in South Africa, in 6 research sites in 5 provinces serving communities with high burdens of TB and MDR-TB, focusing mainly on children below 5 years of age.

“There have been many advancements in the science around preventing drug-susceptible TB, but very little rigorous data on preventing drug-resistant TB,” said Professor Anneke Hesseling, Director of the Desmond Tutu TB Centre and the overall Principal Investigator of the TB-CHAMP trial, at Stellenbosch University. “We have now found a way to safely protect children when an adult in the household has MDR-TB. The importance of safeguarding our children from drug-resistant disease cannot be underestimated. The benefit to children, their families and communities may be substantial.”

“MDR-TB is one of the toughest diseases to cure, and children have always been the most neglected patients,” said Professor James Seddon, co-Principal Investigator from TB-CHAMP from Stellenbosch University. “In finding a new way to keep children safe when MDR-TB afflicts a family member, we help the whole family recover that much faster from the trauma that the disease inflicts—not just from a health perspective, but from economic and mental health perspectives as well.”

“Over 450,000 people develop multidrug-resistant TB each year. Drug-resistant TB can be devastating for patients and their families” said Professor Greg Fox, Principal Investigator on the VQUIN trial, from The Woolcock Institute of Medical Research and The University of Sydney. “We now have evidence that people with early infection can be protected from becoming sick due to drug-resistant TB. This six-month once-daily treatment can protect adults, children and adolescents and young kids from the physical, social and financial consequences of drug-resistant TB.”

“Research to prevent and treat tuberculosis in children has been treated as an afterthought for far too long,” said Dr Philippe Duneton, Executive Director of Unitaid, the largest multilateral funder of TB research and development globally. “Unitaid is pleased to be a part of efforts to elevate children’s needs. This first of its kind evidence into the prevention of drug-resistant TB in children is a major advance that has the potential to protect millions of children from a debilitating illness.”

In the TB-CHAMP trial, 453 children who had been exposed to an adult with MDR-TB in their household were given levofloxacin and only 5 developed MDR-TB. There were very few side events from the medicine. Specifically joint pain and tendonitis, traditionally a concern, were very uncommon in children receiving levofloxacin.

In the VQUIN trial, 2,041 adults and children living with a person with MDR-TB in the household were given six months of levofloxacin and followed up for 30 months. The study took place in 10 provinces across Vietnam. It found that there were 45% fewer cases of TB in the group given levofloxacin compared to the placebo group. A lower number of cases of TB occurred in the placebo group than expected. Overall, levofloxacin was found to be safe and well-tolerated in adults and children.

TB remains one of the top causes of death in children globally and is a one of the top killers of children below 5 years of age. An estimated 30 000 children below 15 years of age develop MDR-TB disease each year, which is complex to treat with current medications, which have many side effects. The cost of treatment is high to families and to health services.

Fewer than 20% of children with MDR-TB are currently diagnosed and treated globally. This makes them one of the most neglected populations affected by TB globally. Many of these children were in close contact with an infectious MDR-TB patient and identifying these children, screening them for TB and offering preventive treatment will be critical to find more cases and also to prevent MDR-TB in children. 

In December 2023, an advisory committee of the World Health Organization will consider new guidelines for MDR-TB preventive treatment. The data from the TB-CHAMP and the VQUIN trials is being shared to inform how these deliberations produce new recommendations for children and adolescents.  The TB-CHAMP and VQUIN trials also completed work on other important considerations such as acceptability of the drug regimen, feasibility, health economics, pharmacokinetics and antimicrobial resistance.

The teams from the TB-CHAMP and VQUIN trials collaborated early on, before the trials were unblinded, and combined their data on efficacy and safety in traditional and novel Bayesian approaches. Jointly, they showed that across both trials, levofloxacin reduced the risk of developing TB by 60%. Novel Bayesian analysis showed similar results for each trial, individually.

‘This novel Bayesian analysis, combining data from trials in two trial populations using novel methodology developed at MRC CTU  at UCL, may pave the way for combining future paediatric and adult trial data, ensuring that children are not left behind. By carefully planning this work in advance, we have been able to present these important findings alongside the main results of the two trials, with greater potential impact on global guidelines and policy” said  Trinh Duong, TB-CHAMP trial statistician and lead for the combined analyses from MRC Clinical Trials Unit at UCL. 

The TB-CHAMP trial was funded by Unitaid, under the BENEFIT Kids project at Stellenbosch University. Unitaid accelerates access to innovative health products and lays the foundations for their scale-up by countries and partners. The trial was also funded by the South African Medical Research Council and the UKRI Medical Research Council through a trial grant to Stellenbosch University, with support from the Department of Health and Social Care, the Foreign, Commonwealth & Development Office, the Global Challenges Research Fund, the Medical Research Council  and Wellcome, as part of the EDCTP2 programme supported by the European Union.

The VQUIN trial was funded by the Australian National Health and Medical Research Council.




AI model can help predict survival outcomes for patients with cancer

Investigators from the UCLA Health Jonsson Comprehensive Cancer Center have developed an artificial intelligence (AI) model based on epigenetic factors that is able to predict patient outcomes successfully across multiple cancer types. The researchers found that by examining the gene expression patterns of epigenetic factors — factors that influence how genes are turned on or off — in tumors, they could categorize them into distinct groups to predict patient outcomes across various cancer types better than traditional measures like cancer grade and stage. These findings, described in Communications Biology, also lay the groundwork ...

Wearable devices detect circadian disturbances that predict frailty risk in older adults

Brigham researchers found an association between alterations in circadian rest-activity rhythms and risk of frailty incidence in older adults Wearable devices can be used to measure a variety of signs and signals related to our health. A new study by researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, suggests that such devices may also be able to help predict older adults at risk of health complications related to frailty. The team found an association between disturbances in daily patterns of rest and activity, or circadian ...

Inequality hotspot map shows where women in agriculture are hit the hardest by the climate crisis

Inequality hotspot map shows where women in agriculture are hit the hardest by the climate crisis
Threats posed by the climate crisis disproportionally affect certain communities and social groups that are more exposed. People living in low- and middle-income (LMIC) countries are at heightened risk. Within these countries, women typically face higher climate risk than men. To show where women working in agri-food systems – systems that encompass production, but also post-harvest handling and distribution – are most threated by climate change, an international team of researchers has developed a hotspot map that identifies and ranks localities by threat level. “We show that significant ...

Reclaiming carbon fibers from discarded composite materials

Reclaiming carbon fibers from discarded composite materials
Minimizing energy consumption is a fundamental element in our journey towards sustainable societies, and advanced materials play a key role in this regard. Carbon-fiber-reinforced plastics (CFRPs) and carbon-fiber-reinforced thermoplastics (CFRTPs) are two prominent examples of composite materials that can significantly improve energy efficiency in various fields of application. These composites are made of carbon fibers embedded in a polymer matrix, such as epoxy resin. Thanks to their low weight and remarkable mechanical strength, CFRPs and CFRTPs can greatly ...

Break free from dependence on Japan by developing core electric vehicle components

Break free from dependence on Japan by developing core electric vehicle components
A research team led by Dr. Jae-woong Ko from the Department of Engineering Ceramics at the Korea Institute of Materials Science(KIMS) has succeeded in localizing silicon nitride bearing ball manufacturing technology for electric vehicle drive modules. KIMS is a government-funded research institute under the Ministry of Science and ICT. This achievement is significant because it overcomes the limitations of foreign dependence and opens up the possibility of domestic supply and demand. Silicon nitride bearing ...

Cannabis use during pregnancy is associated with adverse birth outcomes

Infants prenatally exposed to cannabis are more likely to be born preterm, have a low birth weight, and require neonatal intensive care unit (NICU) care than infants without prenatal cannabis exposure, according to a study published today in the scientific journal Addiction. However, cannabis-exposed infants are not at greater risk of birth defects or death within one year, including sudden unexpected infant death. First author Ms. Maryam Sorkhou comments, “The global increase in cannabis use among women of reproductive age also extends to pregnant women.  ...

Landmark blood test to detect silent, lethal cancer

Landmark blood test to detect silent, lethal cancer
Research that could lead to the first early detection blood test for pancreatic cancer has received critical funding from PanKind, The Australian Pancreatic Cancer Foundation. Pancreatic cancer is one of Australia’s biggest killers, with poor survival rates marred by a lack of distinct symptoms and screening tools needed to detect the disease in its initial stages.  It’s hoped the test will, for the first time, accurately identify patients with early stages of pancreatic cancer – a crucial step towards improving survival ...

A better way to study Parkinson’s disease in the lab could lead to earlier diagnosis

A better way to study Parkinson’s disease in the lab could lead to earlier diagnosis
A recent study published in Progress in Neurobiology and led by researchers at the University of Arizona College of Medicine – Tucson has developed an improved method to study Parkinson’s disease in the lab. Along the way, researchers also uncovered clues that may help scientists figure out how to detect Parkinson’s earlier and point the way toward better treatments. Around a million Americans are living with Parkinson’s disease, a neurological disorder that causes difficulty in movement, balance and cognition. Symptoms worsen until tasks like ...

Night-time radiative warming using the atmosphere

Night-time radiative warming using the atmosphere
Warming has played a crucial role in various industrial and agricultural processes throughout history. Night-time warming, however, presents a distinct challenge due to the absence of solar radiation. During the night, direct radiative heat loss to outer space through the atmospheric transparent window (8-14 μm) can cause temperature to drop below freezing, posing significant threats to agriculture (crops), transportation (outdoor cables), and more.   Traditionally, achieving night-time warming ...

A bi-directional iterative approach to Android automated testing

A bi-directional iterative approach to Android automated testing
With the benefits of reducing time-cost and human efforts, automated testing has been widely used for quality assurance of mobile applications (apps). However, in complex interactive activities, manual testing can achieve higher coverage. However, the effectiveness of manual testing is highly dependent on the vital User Operation Process (UOP) of experienced testers. To solve the problems, a research team led by Zhenyu CHEN and Chunrong FANG published their new research on 15 Oct 2023 in Frontiers of Computer Science co-published ...


Tracing how the infant brain responds to touch with near-infrared spectroscopy

These are the world's most effective charities

When is an aurora not an aurora?

Advisory panel issues field-defining recommendations for US government investments in particle physics research

Doctors discover many patients at UNC’s Inflammatory Bowel Disease Clinic screen positive for malnutrition

BNL: Advisory panel issues field-defining recommendations for U.S. government investments in particle physics research

International collaboration uses faculty member’s research on ancient Roman migration, seeks to understand Balkan genomic history

USF Health Heart Institute doctors are upbeat about cardiac regeneration

AI-driven breakthroughs in cells study: SFU-UBC collaboration introduces "MCS-detect" for advancements in super-resolution microscopy

Advisory panel issues field-defining recommendations for investments in particle physics research

$3.8 million NIH grant to fund Southwest Center on Resilience for Climate Change and Health

What happens when the brain loses a hub? 

Study reveals Zika’s shape-shifting machinery—and a possible vulnerability

RIT leading STEM co-mentoring network

Genetic mutations that promote reproduction tend to shorten human lifespan, study shows

CAMH develops potential new drug treatment for multiple sclerosis

Polyethylene waste could be a thing of the past

A dynamic picture of how we respond to high or low oxygen levels

University of Toronto researchers discover new lipid nanoparticle that shows muscle-specific mRNA delivery, reduces off-target effects.

Evolving insights in blood-based liquid biopsies for prostate cancer interrogation

Finding the most heat-resistant substances ever made

Time-tested magnesium oxide: Unveiling CO2 absorption dynamics

Engaging heterosexual men more effectively could slash HIV infections in Uganda

A fork in the rhod: Janelia researchers unveil comprehensive collection of rhodamine-based fluorescent dyes

The Gerontological Society of America congratulates new 2023 awardees

Texas A&M Institute part of national effort to harness nuclear laser fusion for limitless energy

How health system hesitancies contributed to COVID risks

Stand Up to Cancer names Julian Adams, Ph.D., President and CEO

Immersive VR goggles for mice unlock new potential for brain science

Racial and ethnic differences in hospice use among Medicaid-only and dual-eligible decedents

[] Two new clinical trials find first-ever safe and effective treatment to prevent multidrug-resistant TB in both children and adults: Results presented at the Union Conference in Paris
The TB-CHAMP Phase 3 Clinical Trial tested levofloxacin in children as part of the BENEFIT Kids project led by the Desmond Tutu TB Centre at Stellenbosch University and funded by global health organization Unitaid and others